Literature DB >> 4825114

Heparin prophylaxis against fatal postoperative pulmonary embolism.

S Sagar.   

Abstract

Low-dose heparin prophylaxis against fatal pulmonary embolism has been studied in a random and prospective trial in 300 patients over the age of 50 who underwent major surgery. A dose of 5,000 IU mucous heparin sodium given two hours preoperatively and for five days post operatively prevented fatal pulmonary embolism in all 156 patients so treated, whereas out of 144 patients in the unheparinized group 6 (4.2%) died of pulmonary embolism. This difference is statistically significant. There was no increase in operative or post-operative bleeding or in the formation of wound haematomas in the heparinized group.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4825114      PMCID: PMC1610370          DOI: 10.1136/bmj.2.5911.153

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  4 in total

1.  Controlled trial of two regimens of subcutaneous heparin in prevention of postoperative deep-vein thrombosis.

Authors:  I C Gordon-Smith; L P Le Quesne; D J Grundy; J F Newcombe; F J Bramble
Journal:  Lancet       Date:  1972-05-27       Impact factor: 79.321

2.  The detection of venous thrombosis of the legs using 125-I-labelled fibrinogen.

Authors:  C Flanc; V V Kakkar; M B Clarke
Journal:  Br J Surg       Date:  1968-10       Impact factor: 6.939

3.  Prophylaxis of pulmonary embolism.

Authors:  N L Browse
Journal:  Br Med J       Date:  1970-06-27

4.  Prevention of fatal postoperative thromboembolism by heparin prophylaxis.

Authors:  J G Sharnoff; G DeBlasio
Journal:  Lancet       Date:  1970-11-14       Impact factor: 79.321

  4 in total
  2 in total

1.  [Perioperative prevention of thromboembolism in gynecology].

Authors:  W E Schreiner
Journal:  Arch Gynecol       Date:  1986

Review 2.  Pulmonary embolism: current therapeutic concepts.

Authors:  D A Tibbutt; C N Chesterman
Journal:  Drugs       Date:  1976       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.